Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

LUCENTIS DIN 02425629

Status: Marketed
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: RANIBIZUMAB
Available to quote

Health Canada record

Active ingredient(s)RANIBIZUMAB 10 MG
Dosage formSolution
RouteIntravitreal
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCS01LA04 RANIBIZUMAB
Original market date18-Sep-2014
Current status date18-Sep-2014
SourceHealth Canada DPD

Establishment licence of the holder

Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing RANIBIZUMAB

DINProductCompanyFormStrengthStatus
02296810LUCENTISNOVARTIS PHARMACEUTICALS CANADA INCSolutionRANIBIZUMAB 10 MGMarketed
02525852MELVIZOSAMSUNG BIOEPIS CO., LTDSolutionRANIBIZUMAB 10 MGMarketed
02542250RANOPTOTEVA CANADA LIMITEDSolutionRANIBIZUMAB 10 MGMarketed
02568942RANVUAPOTEX INCSolutionRANIBIZUMAB 10 MGApproved
02568950RANVUAPOTEX INCSolutionRANIBIZUMAB 10 MGApproved
02530589SUSVIMOHOFFMANN-LA ROCHE LIMITEDSolutionRANIBIZUMAB 100 MGApproved
Request a quote for LUCENTIS

How to read a Canadian DIN record